GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Concept Inc (NAS:VERO) » Definitions » ROE %

Venus Concept (Venus Concept) ROE % : 0.00% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Venus Concept ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Venus Concept's annualized net income for the quarter that ended in Dec. 2023 was $-44.46 Mil. Venus Concept's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $-13.09 Mil. Therefore, Venus Concept's annualized ROE % for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for Venus Concept's ROE % or its related term are showing as below:

VERO's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.29
* Ranked among companies with meaningful ROE % only.

Venus Concept ROE % Historical Data

The historical data trend for Venus Concept's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Concept ROE % Chart

Venus Concept Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only -107.23 -138.01 -54.04 -178.24 -

Venus Concept Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -454.96 -1,071.96 - - -

Competitive Comparison of Venus Concept's ROE %

For the Medical Devices subindustry, Venus Concept's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Concept's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Concept's ROE % distribution charts can be found below:

* The bar in red indicates where Venus Concept's ROE % falls into.



Venus Concept ROE % Calculation

Venus Concept's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-37.25/( (8.093+-14.019)/ 2 )
=-37.25/-2.963
=N/A %

Venus Concept's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-44.464/( (-12.17+-14.019)/ 2 )
=-44.464/-13.0945
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


Venus Concept  (NAS:VERO) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-44.464/-13.0945
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-44.464 / 72.528)*(72.528 / 96.2875)*(96.2875 / -13.0945)
=Net Margin %*Asset Turnover*Equity Multiplier
=-61.31 %*0.7532*N/A
=ROA %*Equity Multiplier
=-46.18 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-44.464/-13.0945
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-44.464 / -45.296) * (-45.296 / -30.536) * (-30.536 / 72.528) * (72.528 / 96.2875) * (96.2875 / -13.0945)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9816 * 1.4834 * -42.1 % * 0.7532 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Venus Concept ROE % Related Terms

Thank you for viewing the detailed overview of Venus Concept's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Concept (Venus Concept) Business Description

Traded in Other Exchanges
N/A
Address
235 Yorkland Boulevard, Suite 900, Toronto, ON, CAN, M2J 4Y8
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Heal, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
Executives
Anthony Natale director 235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Ross Portaro officer: President Global Sales 235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Michael Willingham Masters 10 percent owner 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Silva Rajiv De director, officer: Chief Executive Officer 1400 ATWATER DRIVE, MALVERN PA 19355
Stanley Tyler Hollmig director 235 YORKLAND BLVD, SUITE 900, TORONTO Z4 M2J 4Y8
Hemanth Jacob Varghese officer: President/Chief Bus. Officer 330 JOICEY BOULEVARD, TORONTO A6 M5M2W1
Marlin Fund, Limited Partnership 10 percent owner MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Masters Capital Management Llc 10 percent owner 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Fund Iii, Limited Partnership 10 percent owner MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Marlin Master Fund Offshore Ii, Lp 10 percent owner WAYSTONE CORP SV (CAYMAN) LTD, STE 5B201, FL 2, 1 NEXUS WAY, CAMANA BAY, BOX 1344, GRAND CAYMAN E9 KY1-1108
Mss Vc Spv Lp 10 percent owner C/O MASTERS SPECIAL SITUATIONS, LLC, 3060 PEACHTREE ROAD, NW, STE.1425, ATLANTA GA 30305
Marlin Fund Ii, Limited Partnership 10 percent owner MASTERS CAPITAL MANAGEMENT, LLC, 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Masters Special Situations, Llc 10 percent owner 3060 PEACHTREE ROAD NW, SUITE 1425, ATLANTA GA 30305
Penna Domenic Della officer: Chief Financial Officer 235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8
Anna Georgiadis officer: VP, Global HR 235 YORKLAND BLVD., SUITE 900, TORONTO A6 M2J 4Y8

Venus Concept (Venus Concept) Headlines